Cargando…

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults

PURPOSE: We evaluated the outcomes of decitabine as first-line treatment in older patients with acute myeloid leukemia (AML) and investigated the predictors, including a baseline mini nutritional assessment short form (MNA-SF) score, of response and survival. PATIENTS AND METHODS: Between 2010 and 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Kwai Han, Cho, Jinhyun, Han, Boram, Kim, Se Hyung, Shin, Dong-Yeop, Hong, Junshik, Kim, Hawk, Kim, Hyo Jung, Zang, Dae young, Yoon, Sung-Soo, Jin, Jong-Youl, Lee, Jae Hoon, Hong, Dae-Sik, Park, Seong Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410295/ https://www.ncbi.nlm.nih.gov/pubmed/32760083 http://dx.doi.org/10.1371/journal.pone.0235503

Ejemplares similares

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
por: Park, Hyunsung, et al.
Publicado: (2017)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
por: Kim, Seungyoun, et al.
Publicado: (2021)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry
por: Yoo, Kwai Han, et al.
Publicado: (2021)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis
por: Yi, Hyeon Gyu, et al.
Publicado: (2014)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
por: Labrador, Jorge, et al.
Publicado: (2022)

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine
por: Yi, Jun Ho, et al.
Publicado: (2018)

Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia
por: Huang, Jiayu, et al.
Publicado: (2018)

Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
por: Li, Jianyong, et al.
Publicado: (2015)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells
por: Li, Lanzhu, et al.
Publicado: (2021)

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
por: Do, Young Rok, et al.
Publicado: (2020)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
por: Zhu, Jun-Feng, et al.
Publicado: (2022)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness
por: Jacob, Linu A., et al.
Publicado: (2015)

A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma
por: Park, Seong Kyu, et al.
Publicado: (2011)

COVID-19 pneumonia concurrent with newly diagnosed chronic myelogenous leukemia
por: Kim, Chul Soo, et al.
Publicado: (2022)

Thyroid autoimmunity in children and adolescents with newly diagnosed type 1 diabetes mellitus
por: Jung, Eui Seok, et al.
Publicado: (2014)

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia
por: Park, Yumi, et al.
Publicado: (2018)

RTK-RAS pathway mutation is enriched in myeloid sarcoma
por: Choi, Mihong, et al.
Publicado: (2018)

Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia
por: Dou, Liping, et al.
Publicado: (2019)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse
por: Kim, Se Hyung, et al.
Publicado: (2010)

Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype
por: Kim, Sang-A, et al.
Publicado: (2018)

Clinical insights into hematologic malignancies and comparative analysis of molecular signatures of acute myeloid leukemia in different ethnicities using an artificial intelligence offering
por: Snowdon, Jane L., et al.
Publicado: (2021)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
por: Kim, Hyeong Su, et al.
Publicado: (2018)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

Effect of Oxcarbazepine on Language Function in Patients With Newly Diagnosed Pediatric Epilepsy
por: Han, Min Jeong, et al.
Publicado: (2023)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)
por: Yoon, Dok Hyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a5elbqo1eq3i2cgisklae70ekt